» Articles » PMID: 10990069

Expression of Cyclin D1, Ki-67 and PCNA in Non-small Cell Lung Cancer: Prognostic Significance and Comparison with P53 and Bcl-2

Overview
Journal Acta Histochem
Specialty Biochemistry
Date 2000 Sep 16
PMID 10990069
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Uncontrolled cell proliferation is the hallmark of malignant tumours. Thus, the proliferative potential of tumour cells is an important prognostic factor. However, evaluation of the prognostic significance of the expression of proteins involved in regulation of cell proliferation remains controversial. In the present study, expression of Ki-67, PCNA and cyclin D1 was estimated in a group of 89 surgically resected non-small cell lung carcinomas using immunohistochemistry. The results were compared with expression of bcl-2 and p53 and with clinicopathological parameters including patients' survival. Ki-67 and PCNA were found to be moderately and highly expressed in 39% and 44% of the tumours, respectively. There was a strong correlation between Ki67 and PCNA expression. Forty five of 88 tumours (51%) showed overexpression of cyclin D1. Surprisingly, cyclin D1 was mainly localized in the cytoplasm and only a small group of tumours (9/88, 10%) showed nuclear staining as well. Bcl-2 and p53 expression was observed in 69% and 30% of the tumours, respectively. All these markers were found to be independent of clinicopathological parameters, except for Ki-67 and bcl-2 expression, which was associated with squamous cell carcinomas. It is concluded that none of the markers that were studied can be used as an independent prognostic factor, whereas the following combinations of markers may have favourable prognostic value: p53 positivity and low Ki-67 expression, p53 positivity and lack of cyclin D1 expression, bcl-2 positivity and low Ki-67 expression, and lack of cyclin D1 expression and low Ki-67 expression.

Citing Articles

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations.

Shi C, Zhang C, Fu Z, Liu J, Zhou Y, Cheng B Acta Pharm Sin B. 2023; 13(6):2613-2627.

PMID: 37425047 PMC: 10326255. DOI: 10.1016/j.apsb.2023.03.007.


β-caryophyllene oxide induces apoptosis and inhibits proliferation of A549 lung cancer cells.

Shabana S, Gad N, Othman A, Mohamed A, El-Missiry M Med Oncol. 2023; 40(7):189.

PMID: 37233859 PMC: 10220129. DOI: 10.1007/s12032-023-02022-9.


High Expression of Long Noncoding RNA PCNA-AS1 Promotes Non-Small-Cell Lung Cancer Cell Proliferation and Oncogenic Activity via Upregulating CCND1.

Wu C, Zhu X, Xia L, Wang L, Yu W, Guo Q J Cancer. 2020; 11(7):1959-1967.

PMID: 32194807 PMC: 7052854. DOI: 10.7150/jca.39087.


Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients.

Wei D, Chen W, Meng R, Zhao N, Zhang X, Liao D Respir Res. 2018; 19(1):150.

PMID: 30103737 PMC: 6088431. DOI: 10.1186/s12931-018-0843-7.


A potential prognostic biomarker SPC24 promotes tumorigenesis and metastasis in lung cancer.

Zhou J, Yu Y, Pei Y, Cao C, Ding C, Wang D Oncotarget. 2017; 8(39):65469-65480.

PMID: 29029446 PMC: 5630346. DOI: 10.18632/oncotarget.18971.